Movement Alert｜Boston Scientific Rises 3.21% in Regular Trading, New-Gen Prostate Treatment Device Rezum EVO Approved in China

Market Focus

Aug 19

On August 19, Boston Scientific rose 3.21% in regular trading, trading at $52.41/share with turnover of $163 million.

The rally was driven by the announcement that Boston Scientific's new-generation thermal vapor therapy device Rezum EVO received approval from China's National Medical Products Administration for the treatment of benign prostatic hyperplasia. China has become one of the first markets globally to approve this product. The device represents the latest upgrade to the Rezum thermal vapor treatment platform, featuring an enhanced user interface and improved portability suited for outpatient and day-surgery settings. Rezum EVO will be manufactured locally at Boston Scientific's Shanghai Lingang factory, exclusively supplying the Chinese market.

The approval underscores Boston Scientific's accelerating product localization strategy in one of the world's largest healthcare markets, potentially expanding its urology segment revenue base in the region.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1116996895"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1116996895\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1116996895?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-19 22:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116996895","market":"us","top_or_hot":-1,"title":"Movement Alert｜Boston Scientific Rises 3.21% in Regular Trading, New-Gen Prostate Treatment Device Rezum EVO Approved in China","media":"Market Focus","content":"<p><p>On August 19, Boston Scientific rose 3.21% in regular trading, trading at $52.41/share with turnover of $163 million.</p><p>The rally was driven by the announcement that Boston Scientific's new-generation thermal vapor therapy device Rezum EVO received approval from China's National Medical Products Administration for the treatment of benign prostatic hyperplasia. China has become one of the first markets globally to approve this product. The device represents the latest upgrade to the Rezum thermal vapor treatment platform, featuring an enhanced user interface and improved portability suited for outpatient and day-surgery settings. Rezum EVO will be manufactured locally at Boston Scientific's Shanghai Lingang factory, exclusively supplying the Chinese market.</p><p>The approval underscores Boston Scientific's accelerating product localization strategy in one of the world's largest healthcare markets, potentially expanding its urology segment revenue base in the region.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Boston Scientific Rises 3.21% in Regular Trading, New-Gen Prostate Treatment Device Rezum EVO Approved in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Boston Scientific Rises 3.21% in Regular Trading, New-Gen Prostate Treatment Device Rezum EVO Approved in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-19 22:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 19, Boston Scientific rose 3.21% in regular trading, trading at $52.41/share with turnover of $163 million.</p><p>The rally was driven by the announcement that Boston Scientific's new-generation thermal vapor therapy device Rezum EVO received approval from China's National Medical Products Administration for the treatment of benign prostatic hyperplasia. China has become one of the first markets globally to approve this product. The device represents the latest upgrade to the Rezum thermal vapor treatment platform, featuring an enhanced user interface and improved portability suited for outpatient and day-surgery settings. Rezum EVO will be manufactured locally at Boston Scientific's Shanghai Lingang factory, exclusively supplying the Chinese market.</p><p>The approval underscores Boston Scientific's accelerating product localization strategy in one of the world's largest healthcare markets, potentially expanding its urology segment revenue base in the region.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BSX","symbol_name":"波士顿科学","start_time":0,"source_url":"","article_id":"1116996895","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116996895","pubTimestamp":1787149266,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 19, Boston Scientific rose 3.21% in regular trading, trading at $52.41/share with turnover of $163 million.The rally was driven by the announcement that Boston Scientific's new-generation...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BSX":"波士顿科学"},"translate_title":"动向提醒|波士顿科学常规交易涨3.21%，新一代前列腺治疗设备Rezum EVO在中国获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1},"content_text":"On August 19, Boston Scientific rose 3.21% in regular trading, trading at $52.41/share with turnover of $163 million.The rally was driven by the announcement that Boston Scientific's new-generation thermal vapor therapy device Rezum EVO received approval from China's National Medical Products Administration for the treatment of benign prostatic hyperplasia. China has become one of the first markets globally to approve this product. The device represents the latest upgrade to the Rezum thermal vapor treatment platform, featuring an enhanced user interface and improved portability suited for outpatient and day-surgery settings. Rezum EVO will be manufactured locally at Boston Scientific's Shanghai Lingang factory, exclusively supplying the Chinese market.The approval underscores Boston Scientific's accelerating product localization strategy in one of the world's largest healthcare markets, potentially expanding its urology segment revenue base in the region.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}